RVMDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as RVMDW
Revolution Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$182.15+4.19 (+2.35%)
Close on Oct 19, 2026
- Market cap
- $38.41B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$128.05 (+236.7%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Revolution Medicines, Inc. reported revenue of $0 for fiscal 2025. Free cash flow was -$1.23B.
Revenue
$0
FY2025
Operating income
-$1.63B
TTM Q2 2026
Free cash flow
-$1.23B
TTM Q2 2026
EPS, diluted
-$8.84
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $38.41B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 14.74
- Dividend yield
- –
- Free cash flow yield
- -3.21%
Fundamentals
- Revenue
- $0
- Net income
- -$1.77B
- EPS, diluted
- -$8.84
- Free cash flow
- -$1.23B
- Book value per share
- $12.36
- Diluted shares
- 211M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$1.63B
Net income
-$1.77B
EPS, diluted
-$8.84
Free cash flow
-$1.23B
Reported periodTrailing twelve months